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Background: Considerable emphasis is presently being placed on usage of generic medicines by governments
focussed on the potential economic benefits associated with their use. Concurrently, there is increasing discussion
in the lay media of perceived doubts regarding the quality and equivalence of generic medicines. The objective of
this paper is to report the outcomes of a systematic search for peer-reviewed, published studies that focus on
physician, pharmacist and patient/consumer perspectives of generic medicines.
Methods: Literature published between January 2003 and November 2014, which is indexed in PubMed and
Scopus, on the topic of opinions of physicians, pharmacists and patients with respect to generic medicines was
searched, and articles within the scope of this review were appraised. Search keywords used included perception,
opinion, attitude and view, along with keywords specific to each cohort.
Results: Following review of titles and abstracts to identify publications relevant to the scope, 16 papers on
physician opinions, 11 papers on pharmacist opinions and 31 papers on patient/consumer opinions were included
in this review. Quantitative studies (n = 37) were the most common approach adopted by researchers, generally in
the form of self-administered questionnaires/surveys. Qualitative methodologies (n = 15) were also reported, albeit
in fewer cases. In all three cohorts, opinions of generic medicines have improved but some mistrust remains, most
particularly in the patient group where there appears to be a strongly held belief that less expensive equals lower
quality. Acceptance of generics appears to be higher in consumers with higher levels of education while patients
from lower socioeconomic demographic groups, hence generally having lower levels of education, tend to have
greater mistrust of generics.
Conclusions: A key factor in improving confidence in generic products is the provision of information and
education, particularly in the areas of equivalency, regulation and dispelling myths about generic medicines
(such as the belief that they are counterfeits). Further, as patient trust in their physician often overrules their
personal mistrust of generic medicines, enhancing the opinions of physicians regarding generics may have
particular importance in strategies to promote usage and acceptance of generic medicines in the future.
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Generic medicines are those where the original patent
has expired and which may now be produced by
manufacturers other than the original innovator (patent-
holding) company. The term ‘generic drug’ or ‘generic
medicine’ is commonly understood, as defined by the
World Health Organization (WHO), to mean a pharma-
ceutical product that is usually intended to be inter-
changeable with an innovator product, is manufactured
without a licence from the innovator company and is
marketed after the expiry date of the patent or other ex-
clusive rights [1]. Other definitions of generic medicines
may be subtly different, for example the US Food and
Drug Administration (FDA) defines a generic as: ‘A drug
product that is comparable to a brand/reference listed
drug product in dosage form, strength, route of adminis-
tration, quality and performance characteristics, and
intended use’ [2]; and the European Medicines Agency
(EMA) definition is: ‘A generic medicine is a medicine
that is developed to be the same as a medicine that has
already been authorised (the ‘reference medicine’). A
generic medicine contains the same active substance(s)
as the reference medicine, and it is used at the same
dose(s) to treat the same disease(s) as the reference
medicine. However, the name of the medicine, its ap-
pearance (such as colour or shape) and its packaging can
be different from those of the reference medicine’ [3].
However, all agree on the general requirements that the
product is off-patent, contains an active ingredient in a
previously approved medicine, is shown to be bioequiva-
lent to that previously approved medicine, and has the
same dosage form, route of administration and treat-
ment characteristics.
Global healthcare expenditure is increasing steadily [4]
and generic medicine utilisation is often encouraged as a
cost-containment measure [5], as generic medicines are
generally, but not always, less expensive than their
proprietary counterparts; the manifold reasons for which
(including the lack of necessity to recoup research
and development costs, payer pressures and market
competition) are discussed in a recent review article [6].
As generic medicines can be priced as low as 2–10 % of
pre-patent loss prices, their use can lead to considerable
savings [7, 8]. As a result, emphasis is being placed on
usage of generic medicines by governments focussed on
the potential economic benefits and multiple strategies
have been introduced across countries to enhance their
use [9]. Consequently, there is increasing discussion in
the lay media of perceived doubts regarding the quality
and equivalence of generic medicines. In parallel, there
have been a number of studies completed in diverse
territories that have assessed opinions, knowledge, atti-
tudes and awareness of generic medicines amongst both
healthcare professionals and members of the generalpublic. However, while there have been review papers
that have reported the views of these individual cohorts,
there has not, to date, been a single comprehensive re-
view evaluating and critically appraising, in one easily
accessible paper, the collective literature (that is, collating
views of medicine prescribers, dispensers and consumers
together) in this area. Hence, one of the objectives of this
report is to collate the views of each of the key stakeholder
groups in medicine provision, those being physicians,
pharmacists and patients/consumers.
While many countries have introduced substitution of
prescribed branded medications with less expensive
generic equivalents, as well as other measures to in-
crease the prescribing and dispensing of generic medi-
cines [10–12], it has been reported that negative
opinions held about generic medicines (which can be
generally summarised as the view that generics are less
effective and/or of poorer quality than proprietary,
branded medicines) – by both professionals [13–16] and
members of the general public [17–20] – have the po-
tential to reduce acceptance of generics in healthcare
provision.
It is important to note that strict regulations for bio-
equivalence (that is, a formal demonstration of equivalence
between the generic and the proprietary formulations of
the drug) exist; for example, in the USA [21] and Europe
[22], with studies in the USA having reported that pharma-
cokinetic properties of generic drugs, as determined by ex-
tent of exposure (area under the concentration-time curve
(AUC)) and mean peak serum drug concentration (Cmax),
differed by only 3–4 % on average from those of the origin-
ator [23]. Products manufactured to standards that do not
fulfill key criteria for bioequivalence are not granted mar-
keting authorisation as generic medicines. Furthermore,
meta-analyses and other studies have shown no difference
in outcomes between originator (proprietary) medicines
and their generic equivalents across a wide range of medi-
cine types and clinical issues; for example, cardiovascular
drugs [24], antipsychotics [25], antiepilepsy medicines [26]
and antibiotics [27]. While some controversy remains, as
will be discussed later, there have been repeated attempts
by proprietary manufacturers to cast doubt on the quality
of generic medicines and to hinder entry of generic prod-
ucts into the marketplace; for example, in 2013 the French
Competition Authority levied fines of €40.6 million on
Sanofi-Aventis for disparaging generic versions of Plavix
(clopidogrel) and for discouraging generic substitution of
this product [28].
As much debate still surrounds the topic of usage of
generic drugs – medicines, which, as mentioned earlier
are often vital to attempts to maintain control of health-
care costs – it is important to understand the opinions
held by stakeholders in relation to these medicines and
their usage. Hence the primary objective of this paper is
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that focus on physician, pharmacist and patient opinions
(including perspectives, behaviours, attitudes and know-
ledge, where applicable in different publications) of generic
medicines; and to critically appraise their methodologies
and findings with a view to providing unambiguous under-
standing of available literature, in order to inform re-
searchers and policy makers as to gaps in knowledge and
the challenges that remain regarding increasing usage of
generic medicines. To ensure that all relevant publications
were incorporated into this review a variety of keywords re-
lated to these topics were used for searches and these in-
cluded: ‘perception’; ‘view’; ‘opinion’; ‘attitude’; ‘behaviour’;




Literature published between January 2003 and November
2014, which is indexed in PubMed and Scopus, on the
topic of opinions of physicians, pharmacists and patients/
consumers with respect to generic medicines.
Systematic approach to finding appropriate literature
Searches were performed in PubMed and Scopus in
November 2014 for full articles published on the topic
of perceptions/opinions/behaviours/views relating to
generic medicines amongst the specific stakeholder
groups of physicians/general practitioners, pharmacists
and patients. Any study methodology leading to a publi-
cation within the scope of this review was included. Pa-
pers that were not published in English were excluded.
Only full, original research papers and reviews were in-
cluded. Editorial opinions, letters to the editor and other
‘opinion’-based publications were not included.
Search methodology
Title and abstract fields were searched for publications
containing the words: generic; perception; opinion; atti-
tude; or view, along with the modifiers for each stake-
holder group. For the patient group, both ‘patient’ and
‘consumer’ were searched for; for the pharmacist group,
the word ‘pharmacist’ was used; and for the physician
group both ‘physician’ and ‘general practitioner’ or ‘GP’
were the terms used. Boolean operators were used to
combine search components and truncation was used
with the stakeholder search terms, to capture as many
search results as possible. MeSH (Medical Subject
Headings) terms were made use of where applicable.
For example, the PubMed searches were:
((pharmacist*) OR (“pharmacists”[MeSH Terms] OR
“pharmacists”[All Fields] OR “pharmacist”[All Fields]))
AND (opinion[All Fields] OR (“perception”[MeSHTerms] OR “perception”[All Fields]) OR view[All
Fields]) AND ((“drugs, generic”[MeSH Terms] OR
(“drugs”[All Fields] AND “generic”[All Fields]) OR
“generic drugs”[All Fields] OR “generic”[All Fields]))
AND generic AND (perception OR opinion OR attitude
OR view)[Title/Abstract]
(general practitioner* OR physician*) OR ((“general
practitioners”[MeSH Terms] OR (“general”[All Fields]
AND “practitioners”[All Fields]) OR “general
practitioners”[All Fields] OR (“general”[All Fields]
AND “practitioner”[All Fields]) OR “general
practitioner”[All Fields]) OR (“physicians”[MeSH Terms]
OR “physicians”[All Fields] OR “physician”[All Fields]))
AND (opinion[All Fields] OR (“perception”[MeSH
Terms] OR “perception”[All Fields]) OR view[All Fields])
AND ((“drugs, generic”[MeSH Terms] OR (“drugs”[All
Fields] AND “generic”[All Fields]) OR “generic drugs”[All
Fields] OR “generic”[All Fields]))
(patient[Title/Abstract] OR consumer[Title/Abstract])
AND generic[Title/Abstract] AND (perception[Title/
Abstract] OR opinion[Title/Abstract] OR attitude[Title/
Abstract]) AND generic AND (perception OR opinion
OR attitude OR view)[Title/Abstract]
(patient*[Title/Abstract] OR consumer*[Title/
Abstract]) AND generic*[Title/Abstract] OR
(perception[Title/Abstract] OR opinion[Title/
Abstract] OR attitude[Title/Abstract]) AND
(opinion[All Fields] OR (“perception”[MeSH Terms]
OR “perception”[All Fields]) OR view[All Fields])
AND ((“drugs, generic”[MeSH Terms] OR (“drugs”[All
Fields] AND “generic”[All Fields]) OR “generic
drugs”[All Fields] OR “generic”[All Fields])).
Critical appraisal and synthesis
While no papers were excluded based on a subjective as-
sessment of the quality of the reports – as per criteria
described in the journal Nature Clinical Practice [29]
(specifically, the recommended criteria include: relevance
of the paper to the topic; whether the paper contributes
new knowledge; type of research questions being asked;
whether the study design is appropriate; has the potential
for bias been addressed; was the study completed as per
protocol; did the study test a stated hypothesis; was the
statistical analysis appropriate; do the data justify the con-
clusions drawn; and has potential conflict of interest been
identified) and the Critical Appraisal Skills Programme
(CASP) checklist [30] – emphasis was placed broadly on
what the key results were, whether the results were valid
and whether the studies were relevant to the topic of
stakeholder perceptions of generic medicines.
Data were extracted from the included articles. Patient,
physician and pharmacist perspectives were defined as
first-order constructs, and the authors’ interpretations of
these constructs were defined as second-order constructs.
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The PubMed search returned the greatest number of
publications. The physician/general practitioner search
returned 286 articles, the patient/consumer search
returned 618 articles and the pharmacist search returned
96 articles. The headings and abstracts of those 1,000
publications were reviewed to determine which were
within the scope of this review. Figure 1 shows the ap-
proach taken and the number of publications obtained.
The exclusion of papers was on the basis of reading their
titles and abstracts, and the subsequent determination
that their content was not relevant to this review. In
other words, despite the fact that the search of PubMed
may have identified these papers based on the search
terms used, they were in fact not closely enough related
to the focus of this work (that is, stakeholder perceptions
of generic medicines) to warrant undergoing any appraisal
beyond this. The fact that such papers were identified is a
function of the design of the searches, using the selected
search terms, in a deliberate attempt to ‘capture’ as many
published papers in this field as was possible.
The Scopus searches proved less successful, returning
280 articles relevant to patients, 138 articles relevant to
physicians and 70 articles relating to pharmacists. These
results comprised only publications identified in the
PubMed searches, while failing to identify many, and
did not add any new publications. Hence, followingn = 6
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Fig. 1 Flowcharts of selection methodology by stakeholder groupremoval of duplicate findings, there remained 286 arti-
cles as stated above.
Additional applicable papers were included if refer-
enced in those found in the above described searches.
All of the remaining articles were subjected to critical
appraisal and the findings presented below.
Physicians/general practitioners
Following appropriate exclusion of publications, the litera-
ture search returned only 21 publications internationally,
within the stated study time period, on the topic of phys-
ician perception of generic medicines [15, 16, 31–48], six
of which were not in English [34, 35, 39, 41, 44, 46].
Additionally, one further review on the topic of phys-
ician opinions of generic medicines was found (referenced
in [48]) and included [49]; and one additional article
(which was cited in one of the publications found in the
systematic review) was further included as it was the only
interview-based study that could be found on this topic –
a study of GPs’ views of generic medicines by Hassali et al.
in Melbourne, Australia [50], based on interviews with
ten GPs.
Following determination of applicable publications,
those not published in English [34, 35, 39, 41, 44, 46]
were excluded. Therefore, a total of 16 papers [15, 16,
31–33, 36–38, 40, 42, 43, 45, 47–50] were reviewed for
the physician cohort.n = 5n = 0
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Patient/consumer perception, 
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Following appropriate exclusion of publications, the
literature search returned 11 applicable publications
[13–15, 51–58]. No exclusions were made.
Patients/consumers
Following appropriate exclusion of publications, 36
reports on patient/consumer opinions of generic medi-
cines were published within the defined scope [15, 17–20,
31, 37, 52, 54, 59–85], five of which were not in English
[61, 62, 80, 82, 85]. Therefore, 31 papers were reviewed for
this cohort.
Overall
Some publications had scope encompassing more than
one cohort (for example, perceptions of physicians and
patients), thus an overall total of 52 papers were in-
cluded in this systematic review; see Table 1 for details,
where it can be seen that while 16 papers were found to
be relevant to physicians, 11 papers relevant to pharma-
cists and 31 papers relevant to patients, due to overlap,
the number of papers that underwent critical appraisal
was 52.
Review of reported methodologies
The methodological approach most commonly observed
in the research appraised in this review was the self-
administered questionnaire or survey, where dissemin-
ation either by post or online methods appeared to be
the most frequent routes of questionnaire provision to
participants. The conducting of such research by qualita-
tive means (for example, by interview or focus group)
was also identified, albeit that such reports were found
in smaller numbers.
It is notable that only three physician-specific qualita-
tive research papers were found: studies of GPs’ views in
Pakistan [40]; Australia [50]; and Ireland [48], which
described the outcome of interviews with 11, 10 and 34
participants, respectively.
In the case of pharmacists, only two interview-based
studies were found: 16 participants were interviewed for
a study in Sweden [53]; and 44 for a study in Ireland
[58]. In research into patient views, five interview-based
studies of the opinions of patients were found from Iraq
[75], The Netherlands [66], Norway [63, 72] and Ireland
[17], which interviewed 14, 106, 83, 174 and 42 partici-
pants, respectively. Four focus group studies from South
Africa [71], the USA [19, 78] and Australia [70], which
had 73, 30, 50 and 104 participants, respectively, were
found. Additionally, one mixed-subject qualitative study,
which conducted focus groups with 73 consumers and
semi-structured interviews with 15 healthcare profes-
sionals (six each of which were physicians and pharma-
cists), compared consumers’ and professionals’ opinions,along with in vitro testing of a small number of generic
formulations in South Africa [15].
In summary, the greatest numbers of studies found were
quantitative assessments focused on the patient/consumer
cohort. As is often found in quantitative studies, the num-
ber of participants was comparatively higher than in the
qualitative studies of patient and both professional groups.
However, when viewed collectively, the complementary
methodologies employed by the various research groups
have provided a reasonable breadth and depth of insight
into the knowledge of, and perceptions, opinions and be-
haviours towards, generic medicines within the patient,
physician and pharmacist subject cohorts.
Review of stakeholder opinions
Physicians
One of the articles found was a comprehensive and
clearly presented narrative review, by Hassali et al. [49],
which collated international studies published between
1980 and 2008. This article coalesced the collective
views of physicians as accepting of generic substitution
(GS) under policy and economic pressures, but having
concerns regarding the overall quality, reliability and
switchability of generic drugs. This review further
theorised that those concerns may prevent full adoption
of generic drug prescribing and substitution by physi-
cians, which could lead to escalation in healthcare costs
for governments, insurers or consumers directly [49].
This critical appraisal has gone further and has devel-
oped second-order constructs from the 17 included
articles. During the appraisal process, it became clear
that the articles could be defined as belonging to seven
specific, non-mutually exclusive groups related to:
a) physician reservations regarding generic medicines
[15, 16, 43, 45, 47, 48, 50]; b) physicians’ confidence in
their level of knowledge and understanding of generic
medicines and associated topics [15, 31–33, 38, 40, 48, 50];
c) reference by physicians to use of pharmaceutical in-
dustry source of information regarding generic medi-
cines [16, 32, 33, 36, 42, 45, 50]; d) physicians’
perceived influence of the pharmaceutical industry and
company representatives [15, 16, 32, 33, 36, 37, 40, 42,
45, 47, 48, 50]; e) physicians’ experience of financial in-
centives provided to physicians to influence prescribing
behaviour [15, 36, 40, 45, 47, 48, 50]; f ) physicians’
experience of pressure applied by patients regarding
branded products [15, 16, 32, 33, 36, 40, 48]; and
g) physician belief that education (specifically regarding
aspects of bioequivalence) is required for greater use of
generics in their market (all papers). This classification
emerged only as part of this appraisal; it was not com-
monly used before then by authors of any of the indi-
vidual articles or in the aforementioned review by
Hassali et al. [49].
Table 1 Summary of studies (sorted by reference number)
Location Subject(s) n Type Focus ain findings Reference
Nigeria Pharmacists 154 Questionnaire Perceptions any respondents lacked confidence
the quality of the generics available




Czech Republic Pharmacists 615 Questionnaire Opinions, attitudes, experiences majority of respondents considered
neric drugs as bioequivalent and
erapeutically equivalent.
[14]
small number of pharmacists
lieved that generic products were
lower quality than branded drugs
d expected generics to cause more
verse drug reactions.
South Africa Consumers and
healthcare professionals




opinions, along with testing
of generic formulations
l formulations passed in vitro tests
r quality. Therefore, the study
owed clear differences between
rceptions of quality and actual
ality of medicines, suggesting that
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USA Physicians 506 Questionnaire Perceptions meaningful proportion of physicians
pressed negative perceptions about
neric medications, representing a
tential barrier to generic use. Payers
d policymakers trying to encourage
neric use may consider educational
mpaigns targeting older physicians.
[16]
Ireland Patients 42 Interviews Perceptions riable knowledge about generic
edicines among patients. Although
tients were supportive of their more
idespread use, concerns regarding
fety, clinical effectiveness and
anufacturing quality of generic
edicines were identified.
[17]
Denmark Patients 2,476 Questionnaire Attitudes, beliefs, experiences tients who had once experienced
generic switch were more likely to
cept a future generic switch.
[18]
gative views on generic medicines
ere negatively associated with
itching, while beliefs about medicine



























































Table 1 Summary of studies (sorted by reference number) (Continued)
USA Female patients 50 Focus groups Perceptions Generally favourable perceptions
regarding generic drug discount
programs.
[19]
Study participants believed that generic
medicines were generally effective and
similar to their brand equivalents;
however, there was an association
between severity of illness and
willingness to utilise generic prescription
drugs.
Australia Patients 47 Postal survey Attitudes and perceptions
to generic substitution
with AEDs
Considerable concern was found among
patients with epilepsy about generic
substitution of antiepileptic drugs.
[20]
More clinical data and research on
bioequivalence of generic antiepileptic
medicines may help to address these
concerns.
Canada Patients and physicians 81 patients Questionnaire Interchangeability of warfarin While most patients and physicians
appeared to have accepted the
principle of therapeutic equivalence of
generic and brand name warfarin, a
sizable minority had concerns that
could influence prescribing and
compliance, believing that generic
warfarin was neither as safe nor as
effective as brand name warfarin.
[31]
110 physicians
Slovenia GPs 117 Postal survey Attitudes, generic prescribing The majority of GPs perceived generics
to have the same effectiveness as
branded drugs.
[32]
Slovene GPs were aware of the cost
of prescribed drugs. They were willing
to accept independent academic
detailing to improve their prescribing
and were willing to increase prescribing
generic drugs under certain conditions.
Saudi Arabia Physicians 772 Questionnaire Perceptions and attitudes,
generic prescribing
Most physicians supported generic
substitution, but they indicated that
there were certain clinical situations
where they preferred to use brand
name drugs.
[33]
Greece Physicians 1,204 Postal questionnaire Perceptions Physicians seemed to be open to
prescribing generic medicines, despite
the fact that they did not do so at the
time the article was published. The
expansion of the generics market
should have a positive impact on
















Table 1 Summary of studies (sorted by reference number) (Continued)
USA Patients and physicians 550 patients, 606 physicians Online survey Perceptions in the context
of treatment of epilepsy
out half of physicians were
tremely/very likely to request that
and AEDs not be substituted with
generic.
[37]
rceptions among physicians and
tients did not align with the FDA
sition that generic AEDs have
e same clinical effect and safety
ofile as branded AEDs.
ore research is needed to determine
generic AEDs are bioequivalent in
al-life situations.
Jamaica Physicians 60 Questionnaire Acceptance, perceptions ere were doubts about whether
oequivalence of a generic was
uitable to therapeutic equivalence
an innovator drug. A third of the
ysicians were able to identify at
ast one case in the past year of
nical problems with generic
bstitutes, which they perceived
ould not have occurred with the
novator.
[38]
Pakistan Physicians 11 Semi-structured interviews Knowledge, attitudes,
perceptions
e major themes identified were
owledge of generic medicines,
rceptions regarding generic
edicines, attitude towards generic
edicines and perception towards
arketing strategies of pharmaceutical
dustry for brands and generics, as well
recommendations to further enhance
neric utilisation.
[40]
Pakistan GPs 206 Questionnaire Perceptions, attitudes ose to three-quarters of the
spondents showed correct knowledge
out generic medicines being a ‘copy
the brand name medicines’ and
terchangeable with brand name
edicines’. The majority of respondents
correctly understood that the generic
edicines were less safe than brand
me medicines. The majority of
spondents believed that their





























































Table 1 Summary of studies (sorted by reference number) (Continued)
Italy Family paediatricians 303 Online questionnaire Perceptions, patterns of use Major issues related to scepticism
about reliability of bioequivalence
tests and safety of switchability from
branded to generic equivalents. More
information about generic drugs and
more research in the field
of paediatric pharmacology are
needed to increase the generic
medicine prescription rate.
[43]
Malaysia GPs 87 Postal survey Knowledge, perceptions Although it appeared that GPs had
largely accepted the use of generic
medicines, they still had concerns
regarding the reliability and quality
of such products. GPs need to be
educated and reassured about the




Germany Physicians: psychiatrists 410 Survey Decision-making between
generic and branded
Psychiatrists were more likely to choose
branded drugs when imagining
choosing the drug for themselves
(versus recommending a drug to
a patient).
[47]
Psychiatrists were more likely to choose
generic antidepressants than generic
antipsychotics.
Ireland GPs 34 Semi-structured interviews Perceptions, beliefs,
behaviours
Majority of participating GPs actively
prescribed generic medicines.
Predominantly, participants believed
that generics worked as effectively,
and were of the same quality, as
originator medicines A minority of GPs
were of the view that generics were
manufactured to a poorer quality than





Ireland, UK and Jamaica
Physicians 14 papers Review article Views Physicians lack knowledge of regulatory
requirements imposed on generics.
[49]
1980–2008 Being cheaper than their branded
counterparts raised the concerns of
the physicians about their quality,
safety and effectiveness, especially
in the presence of heavy and successful
















Table 1 Summary of studies (sorted by reference number) (Continued)
Australia GPs 10 Semi-structured interview Perceptions Study suggested that GPs in Melbourne
had mixed attitudes to generic
prescribing.
[50]
Also shows that misconceptions about
safety and efficacy of generic medicines
still persisted among some GPs and
that unless they were sufficiently
educated by interested parties, such
as the government and the generic
medicine industry, this will have a
negative impact on utilisation of
generic medicines in future.
Australia, Canada, France,
Germany and UK
Pharmacists 254 Web questionnaire Attitudes, interchangeability
of dry powder inhalers
Just 6 % of pharmacists considered
that dry powder inhalers were
interchangeable, with a high level of
concern shown about interchangeable
use and with patient confusion being




95 pharmacists Questionnaire Perceptions, attitudes More information for patients is
necessary. Greater levels of acceptance
seen in patients with higher education
levels or those who had discussed
substitution with physician/pharmacist.
[52]
417 patients A majority of patients were willing to
accept generics on recommendation
of healthcare professional.
Sweden Pharmacists 16 Interviews Experiences, attitudes Pharmacists found it positive that
generic substitution decreased the
costs for pharmaceuticals but also
emphasised that the switch can
confuse and worry patients, which
could result in less benefit from
treatment.
[53]
To prevent known confusion and
concern among patients, it is important
that community pharmacists acquire
the necessary tools and knowledge to
manage this situation, and communicate
effectively with patients.
USA Patients, pharmacists 82 patients Postal survey Patient and pharmacist
knowledge of, and attitudes
toward, reporting adverse
events due to using
generic AEDs
More than 92 % of patients and 85 %
of pharmacists agreed that switching
between forms of the same AEDs may



















Table 1 Summary of studies (sorted by reference number) (Continued)
Malaysia Pharmacists 219 Postal questionnaire Views Only 50.2 % of the surveyed pharmacists
agreed that all products that were
approved as generic equivalents can
be considered therapeutically equivalent
with the innovator medicines. The
Malaysian pharmacists had a lack of
information and/or trust in generic
manufacturing and/or approval system
in Malaysia.
[55]
New Zealand Pharmacists 360 Postal questionnaire Views, knowledge 70 % of pharmacists stated there was
no difference in safety between original
brand and generic medicines.
[56]
65 % stated that original brand
medicines were of higher quality than
their generic counterparts, and half
stated that generic medicines and
original brand medicines were equally
effective.
Concerns were raised regarding quality,
safety and effectiveness; however, most
of the pharmacists acknowledged the
economic benefits to the healthcare
system.
France Pharmacists 1,000 Postal survey Opinions, behaviours 90 % of the pharmacists were favourable
to the implementation of generic
substitution. 42.5 % declared they
systematically offered patients the
generic drug, whereas 55 % chose
to target specific populations for
substitution.
[57]
Ireland Community pharmacists 44 Semi-structured interviews Perceptions, attitudes Only a small number demonstrated
some reticence regarding generics.
[58]
89 % of pharmacists reported receiving
patient complaints regarding use of
generic medicine, although 64 %
suggested that this was due to a
nocebo effect (that is, a result of
patients’ preconceived notions that
generics were inferior). Only a minority
(21 %) reported that they had
attempted to educate patients as to
the equivalency of generics.
Germany Patients 804 Survey Perceptions GPs were in an ideal position to
adequately inform their patients about
the equivalence of brand name and
generic drugs. Patients held views that
















Table 1 Summary of studies (sorted by reference number) (Continued)
Norway Patients 281 Written questionnaire Experiences, attitudes 36 % of the patients reported negative
experiences after medication substitution.
[60]
Generic drug substitution was not
considered an equal alternative to
branded drugs by a number of
patients for whom additional
information and support may be
needed.
Norway Hypertensive patients 174 Interviews Challenges of generic
substitution in adherence
One in three said generic substitution
made keeping track of their medications
more demanding.
[63]
A negative attitude towards generics
was significantly associated with low
educational attainment, an increasing
number of drugs, having general
concerns about medicine use and
having received insufficient information
regarding generic substitution.
Finland Patients 256 Questionnaire Preferences Approximately half of the respondents
were strongly price-sensitive, while the
others had other preferences such as
brand or an opportunity to buy the
medicine at a pharmacy, or to have a
physician or a pharmacist as an
information source.
[64]
USA Patients 356 Postal survey Perception of generic AEDs A significant percentage of patients
reported that generic AEDs were
responsible for breakthrough
seizures and increased side effects. A
significant percentage of patients also
reported switching back to a brand
name AED and expressed concern
over pharmacies switching to generic
AEDs without a patient’s or physician’s
consent.
[65]
The Netherlands Patients 106 Interview Attitudes to substitution,
oral atypical antipsychotics
3 % stated that they would be unlikely
to take a generic antipsychotic if their
pharmacist were to substitute it.
[66]
Patients with psychoses/schizophrenia
perceived generic versions of their
antipsychotics as being significantly
different. This perceived difference
lowered their intention of continuing
















Table 1 Summary of studies (sorted by reference number) (Continued)
USA Patients 971 Postal survey Relationship between
beliefs and generic usage
neric drug use was most closely
sociated with communication by
oviders about generics resulting in
mfort with generic substitution.
[67]
USA Patients 1,054 Postal survey Perceptions tients agreed that generics were
ss expensive and better value than
and name drugs, and were just
safe.
[68]
dings may indicate that perceptions
out generic essential medications
ve improved over time. Efforts to
ucate patients could positively
fluence usage of generics.
New Zealand Consumers 441 Questionnaire Knowledge, perceptions,
attitudes
armacists were the main source of
formation regarding generic
edicines followed by doctors and
edia.
[69]
higher level of education had a
rect relationship with having correct
owledge of generics.
any consumers have misconceptions
garding generic medicines.
Australia Patients: senior citizens 104 Focus groups Perceptions monstrated considerable mistrust of
neric medicines. Participants
ghlighted their uncertainty about
e extent of pharmaceutical companies’
fluence on health professionals, the
istrust of foreign generic manufacturers
d scepticism in their equivalence.
[70]
South Africa Consumers 73 Focus groups Perceptions espective of socioeconomic status,
spondents described medicine
ality in terms of the effect the
edicine produced on felt symptoms.
[71]
neric medicines were considered to
poor quality and treated with
spicion.
st, avoidance of feeling ‘second
ss’, receiving individualised care

























































Table 1 Summary of studies (sorted by reference number) (Continued)
Norway Patients: Pakistani
immigrants
83 Interviews Challenges following
generic substitution
e-quarter of the participants were
the opinion that cheaper generic
ugs were counterfeit drugs. Two-thirds
d accepted generic substitution in the
armacy, whereas the remaining
rticipants had either opposed or were
aware of the substitution.
[72]
Finland Public: consumers 1,844 Postal survey Opinions nish consumers considered generic
bstitution a good reform. They also
d confidence in the effect of cheaper
edicines. Savings were the main
ason for accepting generic substitution.
[73]
bstitution was not considered to
use any risk to drug safety.
o main reasons for substituting
ere a desire to save money and
commendation by pharmacists.
male gender, older age and use of
escription drugs were associated
ith refusing.
Japan Patients 1,215 Questionnaire Attitudes to generic
substitution
e public awareness program on
neric drugs should be expanded to
clude more detailed information so
at patients obtain the correct
derstanding of generic substitution.
is critical that physicians and
armacists have the proper
derstanding of generic drug
bstitution and provide the correct
formation to patients.
[74]
Iraq Consumers 14 Face-to-face interviews Perceptions ost of the participants understood
at generics cost less compared with
eir branded counterparts, and their
ysicians and pharmacists had given
em information on generics.
[75]
wever, knowledge of generic
edicines was lacking among
nsumers in Iraq and their primary
ason for using generic medicines






















































Table 1 Summary of studies (sorted by reference number) (Continued)
Finland Public 1,844 Postal questionnaire Opinions on refusal of
generic substitution
Main reasons for generic substitution
refusal were satisfaction with their
current medicine and/or that a decision
on a drug product had been made in
co-operation with their physician. Most
of these individuals indicated that they
would be unwilling to accept generic
substitution in the future.
[76]
USA Patients 172 female patients of
childbearing age
Oral questionnaire Beliefs, perceptions Awareness of the benefits of generics
did not equal preferences for personal
use of generics.
[77]
About a quarter believed that brand
name medications were more effective
than generics.
13.4 % believed that generics caused
more side effects.
USA Patients 30 Focus groups Perceptions, barriers to use Barriers to generic medication use
included: perceptions that generics
are less potent than brand name
medications, require higher doses and,
therefore, result in more side effects;
generics are not ‘real’ medicines;
generics are for minor but not serious
illnesses; the medical system cannot
be trusted; and poor people are forced
to ‘settle’ for generics.
[78]
UAE Renal patients 188 Survey Views on generic substitution 70 % of patients were aware of the
availability of generic medicines.
[79]
31 % felt that generics were not
equivalent or only sometimes equivalent
to branded medicines. Nearly half the
patients stated they would refuse generic
substitution when it became available if
this was just to save the health authority
money.
Germany Patients 126 Questionnaire Perspectives to substitution
in context of treatment
of epilepsy
32 % of the patients who already
experienced a switch to generic AEDs
complained of problems with the
switch. However, patients who had
never switched were more concerned
about generic substitution than those
















Table 1 Summary of studies (sorted by reference number) (Continued)
USA Consumers 183 Survey Factors influencing purchasing Single most influential factor was
lower cost.
[83]
Other factors, including advertisements,
duration of the OTC drug effectiveness,
severity of sickness, preferable form of
OTC medication, safety of the OTC,
relief of multiple symptoms and
preferred company, would persuade





Consumers 20 studies Review article Views, chronological Mixed reactions, related to development
level of country.
[84]
However, reasonably positive attitude
(40–60 %) stable across studies.
1970–October 2008 Positive attitudes not necessarily
translated into increased use of
generic products.















Dunne and Dunne BMC Medicine  (2015) 13:173 Page 17 of 27More specifically, with respect to a) above, in the stud-
ies describing reservations expressed by physicians (and
other healthcare professionals), specific references were
made to: lack of confidence in foreign manufacturers,
particularly those in India and China [45, 48]; doubts
about equivalence [16, 33, 38, 42, 47, 48, 50]; and the ex-
pression of personal preference for branded medications
if required for themselves [16, 47, 48].
Other, less common attitudes expressed related to
physicians reporting breakthrough seizures associated
with GS of an antiepileptic drug (AED) and as a result
many were likely to prefer that generic AEDs were not
used [20, 37, 48]. Significant proportions of physicians
express a preference for brand name medications both
generally [31, 48] and in the case of some specific medi-
cations (in this instance, warfarin) [38]. Also, older phy-
sicians were more likely to have a poorer opinion of
generics [16, 48]; however, despite these stated misgiv-
ings, a majority of physicians were largely accepting of
the use of generic medicines [32, 33, 36, 42, 45, 48].
While some physicians have expressed an expectation
that generics should be cheaper than they are [32], many
state the lower cost of generics (and a consideration
of the patient’s ability to pay) as one of the main fac-
tors affecting their prescription of these medicines
[15, 38, 45, 48]. Other factors affecting use include know-
ledge and reliability of the manufacturer [15, 45, 48] and
the illness being treated [47, 48].
All of the studies appraised were included based on a
subjective assessment of their applicability to the topic,
using the criteria outlined earlier. It was further thought
that, given the low number of studies available, an inclu-
sive approach would lead to a greater chance of captur-
ing all potentially relevant perspectives.
Given the paucity of literature on the topic of phys-
ician attitudes towards generic medicines, it is unsur-
prising that each of the papers contributes some new
information, albeit specific to particular countries or re-
gions (Table 1) and, as such, the published outcomes
may not be readily generalisable. It is also notable that
with relatively few exceptions [15, 36, 40, 42, 50] the re-
searchers utilised questionnaires comprised of closed
questions, many of which relied on Likert scale-type re-
sponses. In almost all cases, the study instruments were
assessed for face validity and pilot tested. However, only
one of the papers reported specific efforts to ensure
appropriate reading level [31], while in three studies
[15, 16, 37] payment was provided to physicians par-
ticipating. Indeed, in one of the studies [37], the payment
considerably altered the expected response rate, acknowl-
edged by the authors who however stated that they be-
lieved the payment did not affect the nature of the
responses provided. It was also noted that with the ex-
ception of a single study [31], no data were presented asto whether the participating physicians freely communi-
cated their perspectives on generic medicines to their pa-
tients, a factor that may influence subsequent consumer
attitudes and behaviour.
Across the 17 papers appraised, varying recruitment
strategies were employed, with a number of the research
groups stratifying participants, albeit with a wide range
of response rates. However, recruitment biases were
evident in a subset of these [31, 37, 38, 40, 42, 45], with
the most challenging bias involving recruitment of
participants based on databases of suitable practitioners
provided by representatives of the pharmaceutical in-
dustry [42].
On a positive note, one study assessing the attitudes
and underlying rationales of psychiatrists towards gen-
eric products [47] deserves mention. The authors, recog-
nising a potential bias risk associated with the fact that
all participants were attendees at a single conference,
established elaborate vignette-based scenarios, with mul-
tiple potential questioning delivered to a large number
of participants, enabled further by sophisticated statis-
tical analyses.
Pharmacists
Assessments of pharmacist perceptions of generic medi-
cines have been carried out in a relatively limited num-
ber of countries since 2003: New Zealand [56]; Portugal
[52]; South Africa [15]; Malaysia [55]; France [57];
Ireland [58]; and Sweden [53], and also in relation to
specific medications such as antiepileptic formulations
[54] and inhalers [51]. In fact, as the 11 studies found
here appear to be the only published investigations on
the topic of pharmacist perception of generic medicines,
this appears to be a relatively underexplored area,
internationally.
While critically appraising the papers found, and
attempting a synthesis of their findings, it was evident
that, compared to the physician-focused reports cri-
tiqued above, there was considerably less consensus re-
garding potential second-order constructs. To interpret,
present and discuss the findings of the papers, the
chosen approach was to identify synthetic unifying
themes (an approach described by Fleming [86]). The
four unifying themes identified, comprised of sub-
themes or issues, are detailed in Table 2. The themes
are:
 Pharmacists’ concerns regarding patient understanding
of generic medicines and substitution, patient safety
and compliance with treatments (8/11 papers).
 Pharmacists’ understanding of generic medicines
and substitution, and pharmacists’ confidence in
quality, efficacy and safety of generic medicines
(7/11 papers).
Table 2 Unifying themes and contributing sub-themes from pharmacist papers
Theme Sub-themes Examples of contributing
papers
Pharmacists’ concerns regarding patient understanding of
generic medicines and substitution, patient safety and
compliance with treatments
a. Patient confusion [14, 51–53, 56, 58]
b. Concerns regarding interchangeability [13, 14, 51, 53, 54, 56, 58]
c. Problems with patient compliance [13, 51, 53, 56]
Pharmacists’ understanding of generic medicines and
substitution, and pharmacists’ confidence in quality,
efficacy and safety of generic medicines
a. Level of confidence in knowledge [15, 53, 55, 56, 58]
b. Hospital-based pharmacists versus community pharmacists [13]
c. Need to contact prescriber [51]
d. Belief that the patient prefers physician opinion [52, 53, 58]
e. Requirement for adverse event reporting [54, 56]
Practical aspects of pharmacists’ practice as affected by
generic medicines and substitution
a. Financial incentives by pharmaceutical industry [13, 15, 52, 56–58]
b. Increased pharmacist workload [13, 51, 53, 54, 56, 58]
c. Adverse effect on stocking levels [14, 51, 53]
d. Influence of industry representatives [15, 52, 58]
Pharmacists’ suggestions to improve generic medicine
use and education of stakeholders
a. General education needed [14, 15, 52–58]
b. Patients should have a role in medication decision [51, 53]
c. Need for change in prescribing patterns [52, 53, 57, 58]
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by generic medicines and substitution (10/11 papers).
 Pharmacists’ suggestions to improve generic
medicine use and education of stakeholders
regarding this (10/11 papers).
Interpreting these perspectives, it appears that phar-
macists tend to hold mainly positive views of generics
with respect to their safety and equivalence and support
for GS (for example, German pharmacists were over-
whelmingly cautious (albeit that only dry powder inhalers
were discussed in this study; it is also worth noting that
this study was supported by GlaxoSmithKline who may
have a vested interest in the outcomes of such research)
[51]; and while the French and Irish counterparts were
mainly positive [57, 58]), for some pharmacists there re-
mains cause for concern [15, 51, 55, 56]. Of these, one of
the primary concerns relates to patient safety and, expli-
citly, the potential for confusion to be caused, particularly
in the case of older patients, due to differing appearance
and presentation of generic medicines, which has been
reported to have an impact on medication compliance
[51, 53]. In fact, two suggestions made by pharmacists to
potentially mitigate risk in this area were: a) that patients
be informed and involved in the decision-making process
regarding the selection of medicinal products pro-
vided to them [51]; and b) that an upper age limit be
established such that older patients (possibly more
prone to confusion) would not encounter unfamiliar
medications [53]. Studies have reported perceptions
of increased pharmacist workload associated with genericmedicines, including provision of generic medicine-related
information to patients and variations in stock manage-
ment [58]. Possibly related to these pragmatic topics, one
of the primary pharmacist recommendations was for in-
creased stakeholder education regarding generic medi-
cines and substitution. Further, in one study addressing
both patient and pharmacist perspectives, 78 % of patients
believed themselves to be well-informed regarding generic
medicines while 83 % of their pharmacists perceived a lack
of patient understanding [52]. However, notably, recom-
mendations regarding education are not all focused on
patients and include measures to be taken to ensure that
the pharmacist group have the correct knowledge in order
to aid and facilitate this knowledge transfer to patients
[15, 53, 55–58, 74]. That said, some pharmacists believe
that advice given to patients, by pharmacists, regarding
their medications is less valued or trusted than advice
from prescribing physicians [52, 53].
Each of these 11 papers represented efforts made to
elucidate the views and behaviours of pharmacists. As
shown in Table 2, most of the research groups involved
made efforts to design their study instruments based on
key opinion leader advice and, in the majority of cases,
the instruments were piloted before use.
However, 8 of the 11 papers failed to protect against
recruitment bias, with one dominated by pharmacy
owners who may be influenced by profit margins achiev-
able through dispensing originator medicines and at-
tractive industry bonusing/reimbursement [55]. Another
(originating from South Africa) [16] described an assess-
ment in which both perceptions and experience of
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with actual generic medicine quality. Given the relatively
poor reputation of generic medicine manufacture in
South Africa (as stated in the paper itself ), the outcomes
were predictable and did not add any new information
to the field in that context. The transferability of the
study outcomes beyond South Africa is further ham-
pered by the authors’ acknowledgement that due to their
purposeful sampling in urban (affluent) areas of South
Africa, their results may be confounded by additional
negative biases attributable to those particular commu-
nities and population demographic. While other papers
also focus on specific population groups or countries, it
is the combination of attitudinal perspectives with evalu-
ation of experience of actual specific defined products
that limits transferability in this case.
A common theme in pharmacist-oriented papers was
a focus on the negative connotations of generic medi-
cines as experienced by pharmacists. Only one study
[52] reported incidence (albeit low) of patients request-
ing generic medicines rather than the more frequently
reported reticence of patients. It would be interesting to
meter such incidence as recorded or perceived by phar-
macists and to compare those data with patient-reported
measures. A final comment relates to a possible ‘missed
opportunity’ throughout these studies, whereby study in-
struments have explored pharmacists’ perceptions and
experiences of generic medicine efficacy, safety and qual-
ity, but only 2 of the 11 studies followed this line of
thought by determining what actions the pharmacists
then took with respect to adverse event reporting, an
important facet of pharmaceutical regulation that relies
on post-market monitoring of products (originator or
generic) to ensure that patient safety is assured.
Patients
Patient-focused studies have, relative to the opinions of
healthcare professionals, had comparatively more atten-
tion, internationally. In summary, published reports have
originated in Norway (patients attitudes to generic
substitution) [60], Finland (preferences of patients for
generic and branded over-the-counter (OTC) pain medi-
cines) [64], Portugal (patient perceptions of underuse of
generics and their attitudes towards generic substitution)
[52], South Africa (consumer perceptions of generic
drug quality compared with actual drug quality) [15, 71],
New Zealand (patients’ perceptions, knowledge and atti-
tudes regarding generic medicines and investigation of
patients’ attitudes towards generic substitution of oral
antipsychotics) [66, 69], Iraq (consumers’ knowledge relat-
ing to generic medicines) [75], the USA (patient knowledge
of, and attitudes relating to, formulation switching of anti-
epileptic drugs) [54] and Ireland (patient perceptions of
generic medicines) [17], amongst others.In critically appraising the papers found, and attempt-
ing a synthesis of their findings, it was evident that,
compared to the pharmacist-focused reports critiqued
above, there was greater consensus regarding potential
second-order constructs. To interpret, present and dis-
cuss the findings of the papers, the chosen approach was
to identify synthetic unifying themes [86]. The unifying
themes identified, comprised of sub-themes, are detailed
in Table 3. The themes are:
 Patients’ lack of confidence in generic medicines,
contributed to by initial scepticism, provision of
poor or poorly understood information, and concerns
regarding packaging and/or appearance of generic
medicines (18/30 papers).
 Patients’ actual experiences in using generic
medicines, not exclusively negative, including
difficulties associated with treatment adherence or
compliance (9/30 papers).
 Factors influencing patient acceptance of generic
medicines, including patient involvement in
decision-making, age, income and severity of illness
(7/30 papers).
 Provision of information and education regarding
generic medicines (10/30 papers).
In a 2009 review article on patient views of generic
medicines (reviewing literature up to October 2008),
Hassali et al. [84] determined that patient confidence
and knowledge had improved steadily since the 1970s,
with the greatest levels of acceptance being seen in
developed countries. This growth in confidence was as-
cribed to mass educational efforts and greater communi-
cation amongst healthcare professionals and patients,
although safety and efficacy were stated as being the
main barriers to acceptance of generic substitutions.
Hassali et al. stated that consumers with lower educa-
tional levels tend to have greater mistrust in generics,
and this appears to continue to be the case, as reported
in more recent research [52, 63, 69]. Interestingly, how-
ever, this did not appear to be the case in a study pub-
lished by Kohli and Buller in 2013, who stated that even
though their study population had lower socioeconomic
status and education, more than half of respondents re-
ported choosing generic drugs rather than brand name
drugs [83]. When delved into more deeply, the apparent
disparity is somewhat explained by the fact that while
the latter study is broadly similar to the other three
detailed above with regard to methodology and number
of participants, the focus is solely on generic OTC medi-
cines. In fact, the authors found that, similar to the
Finnish study above (which was inclusive of OTC
medicines), lower cost and number of doses in the pack-
age were important factors that respondents rated as
Table 3 Unifying themes and contributing sub-themes from patient/consumer papers
Theme Sub-themes Examples of contributing papers
Patients’ lack of confidence in generic medicines a. Scepticism [18, 20, 59, 63, 65, 66, 68–72, 76–79, 81]
b. Provision of poor or poorly understood information [19, 59, 63, 70, 77–79]
c. Concerns regarding packaging and/or appearance
of generic medicines
[59, 63, 65, 66, 69, 70, 75]
Patients’ actual experiences in using generic medicines a. Poor experience [59, 60, 63, 65, 72, 76, 81]
b. Not exclusively negative [18, 59, 60, 65, 66, 73]
c. Difficulties associated with treatment adherence
or compliance
[63, 66, 70, 72, 75, 81]
Factors influencing patient acceptance of
generic medicines
a. Patient involvement in decision-making [19, 20, 65, 66, 76]
b. Advanced age incompatible with generic use [60, 73]
c. Income/education level [68, 69, 77]
d. Severity of illness/drug type [19, 63, 68, 69, 77, 78, 81, 83]
e. Nocebo [17, 59]
Provision of information and education regarding
generic medicines
a. Education and support [19, 60, 63, 66, 68, 72, 74, 75, 79, 83]
b. Source of information, including physician
versus pharmacist
[70, 71, 78]
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OTCs. In addition, factors that were determined to have
no statistical significance in influencing consumer pur-
chasing patterns included advice from healthcare provider,
advice from family and friends, look of the package, degree
of sickness (mild), taste of the OTC and greater effective-
ness of the OTC. It is noteworthy though that the authors
did not survey participants about their health insurance
status and whether they received coverage for OTC
medications.
The authors of the 2009 review recommended that
further research in the area of patient views should be
focussed on developing countries, where cost savings are
more urgently needed; and in fact research published
since 2009 has been more focussed on developed coun-
tries, possibly as a result of where research funding is
available to investigate consumer opinions.
The greatest level of poor opinion and mistrust in ge-
nerics is seen in the patient rather than healthcare pro-
fessional cohort. They report negative perceptions in
general as well as in specific terms. In general terms,
views are reported such as: being largely unwilling to
accept, or having mistrust in generics [70, 76]; having
had negative experiences following a generic substitution
[60, 72]; mistrust of foreign manufacturers [70]; and a
belief that cheaper equals inferior [17, 59]. In specific
terms, patients reported breakthrough seizures following
substitution of an AED [20, 37, 65, 81], reported being
advised by a physician not to accept GS for an AED R61
and are of the opinion that poor people are forced to
‘settle’ for generics [59, 78] (in one study nearly half of
the respondents stated that they would refuse a GS if it
was only to save the health system money [79]). Thisreported behaviour is supported by beliefs that generic
medicines are believed to be poor quality, are treated
with suspicion and are considered ‘second class’ within
this cohort [17, 66, 71].
Many patients do not consider generic medicines
equivalent to the branded product [60, 63, 70, 72, 78, 79]
and there is also a belief that brand name medications
are more effective/potent and have fewer side effects
[63, 72, 77, 78]. Furthermore, patients appear to be
more accepting of generics for treatment of minor ill-
nesses but prefer branded medicines for more serious
health problems [19, 69, 78, 81]. Links between GS
and lack of compliance with taking medication can
also be observed: patients have reported that GS made
it more demanding to keep track of their medication
[63, 72] and that variability in packaging or appear-
ance caused issues [17, 70]. Worryingly, in one study
patients were seen to be taking two or more equivalent
medications, concurrently, due to lack of understanding,
following a GS [72]. While many misconceptions are held
within the patient group [69], one particularly disturbing
association can be observed in the literature: some con-
sumers held the belief that generic and falsified (that is,
counterfeit) medicines are the same [15, 72].
There are, however, several studies that report positive
views in the patient group. In a Finnish study a majority
of patients indicated that they did not notice any differ-
ence following a GS [73]. Other studies have shown pa-
tient groups that do not consider generics to pose a
safety risk [17, 68, 73], that they generally accept ge-
nerics as being equivalent [19] and in one study only a
minority believed that brand name medicines were bet-
ter than generics [68]. While perceptions appear to be
Dunne and Dunne BMC Medicine  (2015) 13:173 Page 21 of 27improving over time [68], recent literature in the area of
patient perceptions has a common recommendation
running through it: the continued need for effective in-
formation to be communicated to consumers and for
trusted healthcare professionals to take time to provide
clear education about the equivalence of generic formu-
lations [15, 17, 52, 60, 63, 68, 77, 78]. Knowledge gaps,
often considerable, exist within this cohort [17, 74, 75, 78];
hence education is seen as a key factor to improvement
of confidence in, and therefore usage of, generic medi-
cation. In support of this, one study found that the
provision of a short explanation was seen to have a
positive effect on patient likelihood to accept a generic
[66]. Whether accepting or not, patients wish to be in-
formed as to their healthcare matters, with a view
amongst patients that a GS should not take place with-
out their being informed [17, 65].
While the lower cost of generics is the primary incen-
tive associated with their use [52, 60, 64, 73, 75, 83], it is
interesting that an awareness of the benefits of generics
does not always translate into a preference for their use
[76, 77]. Indeed, a study in Finland [73] showed that
while a majority of patients stated that more generics
should be used, they did not exhibit a preference to use
them themselves.
There appears to be considerable evidence that pa-
tients who have had a previous good experience with a
generic medication are more likely to accept generics in
the future [15, 18, 52, 67, 69, 74] and, as patients who
have never experienced a GS appeared to be more con-
cerned about taking a generic than those who had [81],
this reinforces the importance of the role of healthcare
professionals and of provision of accessible information
to the patient cohort. In fact, several studies have re-
ported patient trust in healthcare professionals and their
acceptance of recommendations of generic medicines,
by trusted professionals, despite their own lack of confi-
dence in GS [17, 52, 66, 71, 73–75].
In critically appraising these 30 studies, particular at-
tention was paid to the quality of the study design, the
analysis and interpretation of the data, as described by
the authors, and to the conclusions drawn. A number of
potential confounding factors were evident:
 In the majority of the studies, there was an apparent
bias towards investigating negative connotations of
patient perceptions of generic medicines. Only a
subset of the studies investigated the positive
experiences of patients, and whether they had
preferences for or had habitually requested generic
medicines over originator products [19, 20, 66, 68,
74, 77, 81, 83]. In one specific case, data are
presented only for patients who had declined
recommended generic medicines [76]. In determining attitudes and perceptions of
patients, many of the studies relied on self-
reported questionnaires. In doing so, there is an
assumption made that the information provided by the
patients regarding their exposure to generic products
and, indeed, their stated illnesses are factual. Only four
of the research groups correlated patient-derived
information with patient records [18, 67, 78, 79].
 In almost all cases, the authors failed to comment
on the potential impact of incomplete/non-returned
questionnaires and the information that they may
have provided. However, in one specific case, an
assumption is made that non-return of data equated
to dissatisfaction with generic medicines, leading
to a statement that a third of patients held that
view [59]. This is problematic, as the missing
data corresponded to almost 50 % of the ‘dissatisfied’
cohort. The researchers would have been more
accurate in stating that ‘… approximately one-sixth
of patients explicitly stated dissatisfaction’.
 Many of the studies use convenience samples raising
a query regarding the generalisability of the results
to the specific population being evaluated; indeed,
transferability of much of the data are hampered
by a lack of information regarding participant
socioeconomic status and educational background.
Similarly, many of the studies focus on narrowly
defined cohorts such as those on specific medications
(for example, antihypertensive, antiepileptic) or
culturally discrete communities (for example,
immigrant Pakistanis in Norway, post-apartheid
older patients in South Africa or poorly educated black
females in rural areas of southern states of the USA).
 Validity is questionable in reports with low response
rates (for example, 6 % [20]).
 Payment for participation is recorded in two papers,
with some indication that the responses obtained
from participants may have been different from
those expected, possibly due to wishing to provide
perceived acceptable answers [19, 78].
 Especially pertinent to the context of this review,
almost all of the studies failed to take into
consideration survey readability (for example,
Flesch Reading Ease or Flesch–Kincaid Grade
Level assessments) and the influence of that on
participant responses.
Discussion
This review is the first (to the authors’ knowledge) to in-
clude the views of all three of the main stakeholders in
generic medicine usage (prescribers, dispensers and con-
sumers). Quantitative studies have been the main ap-
proach taken in determining the views and behaviours of
the cohorts in the past. These are generally in the form
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or by post. Qualitative studies [15, 17, 19, 53, 72, 75, 78]
were also identified, albeit that such reports were found
in smaller numbers (only 7 of the 50 publications made
use of qualitative methods). These studies have made a
significant contribution, however, in showing, for ex-
ample, that providing patients with a short explanation
about generic medicines had a significantly positive ef-
fect on their willingness to take them [66], reinforcing
the perception that there remains a need for information
provision and education. For example, one qualitative
study referred to in this review has shown that correct
understanding of generic medicines by the general pub-
lic, as determined by previous quantitative, survey-based
studies, may be overestimated (that is, confusion in the
patient cohort between the words ‘generic’ and ‘genetic’)
[17]. However, irrespective of choice of qualitative or
quantitative approach, similar trends in opinions and
beliefs held have been reported.
In all three cohorts, it appears that opinions of generic
medicines have improved over the years but that some
mistrust appears to remain, most particularly in the
patient group. Our observations in this regard comple-
ment the findings of a recently published review of the
knowledge and perceptions of patients regarding gen-
eric medicines [87]. Both studies show that patients
tend to prefer branded medications, that they have in-
sufficient knowledge and information about generics
(thus leading to the need for appropriate educational
interventions), and that physicians and pharmacists
play a key role in the promotion of generic medicines
to patients and in patients’ acceptance of generic
substitution.
The physician group shows some level of lack of confi-
dence, although not to the same extent as consumers. It
is interesting to note that many comments made by phy-
sicians with regard to lack of confidence in generic med-
icines (as reported earlier) appear to be in contradiction
with the literature, where many examples of the use of
generic medicines with no negative clinical impact are
provided. In fact, a systematic review which summarised
the clinical evidence comparing generic and brand name
drugs used in cardiovascular disease, which included
randomised controlled trials (RCTs) on narrow thera-
peutic index drugs such as warfarin, concluded that
while the evidence does not support the notion that
brand name drugs used in cardiovascular disease are su-
perior to generic drugs, a substantial number of journal
editorials counsel against the interchangeability of gen-
eric drugs [24]. This contradiction in the literature may
go some way to explaining physician confusion and lack
of trust in generics. However, it is important to remain
cognisant that while there is much evidence to support
equivalence and interchangeability in many areas ofmedicine, there are areas where substitution should con-
tinue to be approached with caution, for example, in the
prescribing and usage of AEDs.
Pharmacists exhibit the greatest degree of positive
opinion, and acceptance, of generic medicines. Such
mistrust is likely to be substantiated, and possibly fur-
thered, by recent investigations by the FDA which
showed that medications previously designated as
equivalent and interchangeable were in fact not thera-
peutically equivalent; for example, bupropion (trade
name Wellbutrin) [88] and more recent investigations
into the therapeutic equivalence of methylphenidate
hydrochloride generics (trade name Concerta) [89]. It is
worth noting that these issues were both seen in ex-
tended release preparations (with no issues reported for
immediate release formulations) and that concerns with
modified or extended release preparations have been
described elsewhere [90, 91].
There tends to be agreement that provision of
education – particularly, but not exclusively, to the pa-
tient cohort – is one of the key factors to improving con-
fidence in, and hence usage of, generic medications. A
common finding is that acceptance of generics appears to
be higher in consumers with higher levels of education
[52, 69] and patients from lower socioeconomic demo-
graphics, hence having lower levels of education, tend to
have greater mistrust of generics [84], with the exception
of the findings of Kohli & Buller in 2013 [83], discussed
earlier. However, there may be some bias amongst re-
searchers in focusing on negative connotations while
disregarding the equally interesting area of patient ac-
ceptance and even, possibly, preference for generic medi-
cines. Indeed, when investigated, positive attitudes were
seen to arise due to good experiences with generic medi-
cine use or for economic reasons.
There appears to be a strongly held belief, particularly
in the patient group, that less expensive equals lower
quality [17, 60, 77], reinforcing the need for ‘myth-
busting’ education. While consumers may hold that
opinion due to experience with other consumer products,
the same principles do not apply to pharmaceuticals be-
cause of the highly regulated nature of medicine manu-
facture and marketing approval requirements. Provision
of education on these topics to both consumers and phy-
sicians (who have exhibited a lack of knowledge in the
regulation of medicines in some publications [32, 45, 49])
could be instrumental to improving confidence in ge-
nerics by providing greater understanding as to why, in
the case of generic medicines, lower prices do not equate
with poorer levels of quality or efficacy. However, it is
interesting that while patients value the opinions of,
and information provided to them by, physicians and
pharmacists, there is some patient preference for
physician-sourced guidance (for example, in South Africa
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macists, as discussed earlier.
Of potential importance to policy makers is the on-
going trend, reported in the 2009 review [84] and again
in a 2013 study [83], that positive attitudes towards ge-
nerics amongst the consumer group do not necessarily
translate into increased usage of generic products.
While acknowledging the fact that very few studies will
be perfect in both design and completion, and that con-
tingencies in implementation of study protocols can mar
any project, the critical appraisal of the studies included
here highlights some points that may confound or limit
the data they generated. In summary, however, some of
the physician-oriented papers involved recruitment
biases, the most notable of which were due to use of
pharmaceutical industry-derived databases for partici-
pant selection [14] and payment to physicians for their
inclusion in studies [9, 16, 18]. With respect to
pharmacist-oriented papers, there were again recruit-
ment biases in some reports, mainly due to relatively
limited geographic distribution of participants, and a po-
tentially dominant focus on reporting negative connota-
tions of generic medicines while, arguably, missing
opportunities to report and discuss positive attributes of
generic medicines and substitution from the pharma-
cist’s perspective. Given that this appraisal involved com-
paratively greater numbers of patient-focused studies
than those featuring perceptions of other stakeholders, it
is perhaps reasonable that the greatest number of con-
founders were determined in the larger collection. Spe-
cifically, in the majority of the studies, there was an
apparent bias towards investigating negative connota-
tions of patient perceptions of generic medicines. Validity,
transferability, participant selection and understandability
of the study instruments used have also been discussed in
earlier sections, and may in some way challenge the out-
comes of the studies. However, it must be acknowledged
that in most of the studies appraised, the authors
attempted to understand these factors and how they may
have influenced their data generation, analysis and inter-
pretation of outcomes.
Recommendations
Further research may be needed in the area of pharma-
cist opinions as they have a direct impact on patient ac-
ceptance of generic medication and, relative to the other
two cohorts, very little attention has been paid to this
group.
Contradictions and inconsistencies in the literature
need to be addressed, such as the apparent inconsistency
between evidence of equivalency reported in many clin-
ical trials and journal editorial counselling against the
interchangeability of generics in the treatment of cardio-
vascular disease, as reported by Kesselheim et al. in their2008 systematic review [24]. Addressing this would help
to improve understanding and provide clarity to health-
care professionals (whose opinions may be negatively
affected by conflicting and confusing information), and
may, in turn, help to increase trust and confidence in
generic medicines within this cohort.
A considerable amount of research in the area of
equivalence of generic medicines has shown that ge-
nerics can be used safely with no negative clinical impact
[23–27, 92]. However, some discrepancies remain be-
tween patient and professional experiences and the
stated equivalence by regulators [43]. While acknowledg-
ing that there are difficulties in some areas (for example,
with AEDs [20, 37] or the differences in excipients or
salts used in generic formulations [90]), education of
healthcare professionals on the content of the many
studies, which demonstrate that there are no clinical dif-
ferences between generics and originator medicines in
many product classes and disease areas, could help
to improve perceptions of members of these stake-
holder groups towards generic medicines. Furthermore,
provision of the key information from such studies, in a
non-technical, jargon-free and easy-to-understand manner
to consumers, may have a positive impact on consumer/
patient perception of generics. Continuation of such re-
search in this field will ensure new and on-going informa-
tion of equivalence (with some noted exceptions), safety
and quality in the usage of generic medicines.
While many misconceptions are held within the pa-
tient group [69], a disturbing association can be ob-
served in the literature regarding patient belief that
generic and falsified (that is, counterfeit) medicines
are the same [72, 15]. Given that generics are fully
authorised, off-patent versions of branded medica-
tions, and very different from falsified medicines, this
indicates that any educational interventions focused on
this cohort need to include at least some information that
explains the difference between generic and falsified
medicines, in order to remove this falsely held belief as a
source of mistrust of generics.
As several publications report that a previous positive
experience with a generic medicine is more likely to im-
prove patients’ positive opinions of, and confidence in,
generic medicines [15, 67, 69, 18] – combined with the
influence and trust which patients demonstrate in physi-
cians [17, 52] – it is arguable that if physicians (and
pharmacists) spend time explaining the equivalence of
generic medication to a patient at their first encounter,
this will encourage use of the generics and, therefore,
improve future use of generic medications by that
consumer.
Increased usage of generics may be brought about
through implementation of recommendations from a re-
cent review, which suggested increases in International
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which may be to improve patient familiarity with generic
names of medicines and, thus, reduce reliance on brand
names, in addition to reducing patient confusion when
dispensed generic preparations of varying appearance/
packaging on different occasions), financial incentives to
support generic prescribing and prescribing restrictions
or removal of products from reimbursement lists, amongst
other suggestions [93].
Limitations
This review was limited in that PubMed and Scopus
were the only databases used for sourcing literature
(however, PubMed and Scopus combined represent con-
siderable coverage of reputable journals) and that articles
not published in English were excluded from the scope
of this review.
In this review, there was a balance achieved between
the sensitivity of the searches (that is, the capture of as
many relevant papers as possible) versus the specificity
(whereby screening of very large numbers of papers
would be required to identify those relevant to the focus
of this review). These results, whereby PubMed proved
more effective in identifying relevant publications than did
Scopus, mirror results seen by Freeman et al. [94] who re-
ported that PubMed proved more specific than Google
Scholar in locating relevant primary literature when com-
paring effective search databases for drug-related topics.
Furthermore, Falagas et al. [95] reported that the keyword
search with PubMed offers optimal update frequency and
includes online early articles, although Scopus offers more
coverage of journals. PubMed, however, remained an opti-
mal tool in biomedical electronic research [95].
For qualitative reports, the impact of the intricacies of
the relevant social contexts and methodologies (participant
observation, ethnography, interviews, focus groups, tex-
tural or conversational) were not delved into beyond deter-
mining whether represented biases were detrimental to the
findings of the studies.
Recognising that there has been a historical difficulty
in including qualitative research easily into systematic
review methodologies [96], considerable emphasis has
been placed on assessing each of the reports included
here using criteria for assessment of qualitative research
promoted by the British Medical Journal [97] and Letts
et al. [98]. In doing so, instead of detailing each aspect
of each paper, the focus has been placed on the believ-
ability, robustness and transferability of the studies. Be-
yond that, therefore, there is a presumed credibility with
respect to the researchers involved, reinforced to a great
extent by the cumulative validation attributable due to
the clear alignment of individual studies with one an-
other and the triangulation with data presented in the
quantitative papers.With respect to quantitative studies, the question of
whether the cohorts of subjects were (statistically or
demographically) representative of their target commu-
nities was critiqued. Where elements of any paper were
found to be weak in this regard, this has been detailed in
the text above.
Conclusion
While acceptance of generic medications is improving,
substantial mistrust and lack of confidence remains, par-
ticularly within the patient and, to a lesser extent, phys-
ician groups. A key factor in improving the confidence
of these cohorts is the provision of information and edu-
cation, particularly in the areas of equivalency, regula-
tion and in dispelling myths about generic medicines
(such as the belief that they are counterfeits). Moreover,
as patient trust in their physician often overrules their
personal mistrust of generic medicines, improving the
opinions of generics within the physician cohort may be
of critical importance to improve usage and acceptance
of generic medicines in the future. Given that reports in-
dicate that patients who have a positive initial experience
with a generic are more likely to maintain a positive
opinion into the future, the physician–patient relation-
ship and interaction may be key to influencing improving
patient approval of generic medicines. To substantiate this
facet of generic medicines, it may be useful for all stake-
holders were a Cochrane review to be completed in this
area; as of July 2014, a search of the Cochrane Database of
Systematic Reviews found that no Cochrane Review had
been published and no protocol title registered focused on
patient, pharmacist and physician perspectives on generic
medicines (with reference to Cochrane’s Primary Health
Care, Health Care of Older People and Effective Practice
and Organisation of Care groups).
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